About Us

As a high-tech enterprise founded in 2018 by top epigenetic experts, Epiprobe focuses on the molecular diagnosis of cancer DNA methylation and precision theranostics industry. With a profound technology basis, we aim to lead the era of new products to nip cancer in the bud!

Based on Epiprobe core team’s long-term research, development and transformation in the field of DNA methylation with the cutting-edge innovations, combined with the unique DNA methylation targets of cancers, we use a unique multivariate algorithm combining big data and artificial intelligence technology to independently develop an exclusive patent-protected liquid biopsy technology. By analyzing the methylation level of specific sites of free DNA fragments in the sample, the shortcomings of traditional examination methods and the limitations of surgery and puncture sampling are avoided, which not only achieves accurate detection of early cancers, but also enables real-time monitoring of cancer occurrence and development dynamics.